

Interface and Formulary Update - Issue 35

April 2025

Key messages from April 2025 TAG meeting - (ratified by Medicines Optimisation Programme Board)

Commissioning Review Transgender Prescribing	<ul style="list-style-type: none"> • Guidance documents to support prescribing • Treatments to be classified as ADVICE - GP prescribable after consultant/specialist recommendation as Gender Identity Clinics are unable to prescribe medication
Formulary Review Ferric maltol (Feraccru®) for the treatment of iron deficiency anaemia in adults	<ul style="list-style-type: none"> • Recommendation for GREEN classification with restriction. • Additional information required to determine position in therapy. • Further work and discussion required to agree pathway and to confirm and endorse ferric maltol recommendation.
Formulary Review Heylo™ - ostomy care leakage system	<ul style="list-style-type: none"> • BLACK – not commissioned. Not for prescribing in primary or secondary care
Formulary Review Tirzepatide for managing overweight and obesity	<ul style="list-style-type: none"> • Only available via specialist weight management services for managing overweight and obesity. • Not to be prescribed in primary care • Netformulary and local guidance updated

Formulary and Guidance Updates

Formulary Amendments

- **Ketorolac eye drops** – Change in classification to **ADVICE - GP prescribable after consultant/specialist recommendation**
- **Contrelle Activgard** and all related products / brands - **BLACK – Not Commissioned. No prescribing in primary or secondary care**
- **Liraglutide 1.8mg injection** for type 2 diabetes - **ADVICE - GP prescribable after consultant/specialist recommendation**
- **Melatonin Liquid Preparations** - **Red Hospital Only**
- **Omeprazole 10mg/15ml and 20mg/15ml oral solution unit dose sugar free** - **BLACK – Not Commissioned. No prescribing in primary or secondary care**

Guidance Updates

- [TAG Governance](#) documents
- [Home Oxygen](#) Therapy Service
- [Hybrid Closed Loop Systems](#) Implementation Plans
- N+W National Patient Safety Alert – [Shortage of Pancreatic enzyme replacement therapy](#) (PERT)
- **COPD - [N+W Primary Care Guideline](#)**
- **COPD - [Self-Management Plan](#)**
- **COPD - [Rescue Packs](#)** – Quick Reference Guide
- [Bladder & Bowel Continence](#) Product Formulary Prescribing Guide – 2025
- Use of [off-label testosterone](#) in women for hypoactive sexual disorder during the menopause
- [Stoma](#) Fair Use Policy – March 2025 update
- Guidance for prescribing [oral nutritional supplements](#) (ONS) for infants & children
- East of England [Hypertension](#) Protocols

Shared Care Updates

Melatonin for Sleep Disorders in Children

- Consultant Paediatricians will be able to initiate as appropriate for patients with neurodevelopmental disabilities
- All other indications listed within the shared care agreement remain unchanged and will require referral to specialists

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

Hospital / Specialist Only	TA1036 - Elacestrant (Korserdu®) Oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment
	TA1037 - Pembrolizumab (Keytruda®) Adjuvant treatment resected non-small-cell lung cancer
	TA1038 - Selpercatinib (Retsevmo®) Advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over
	TA1039 – Selpercatinib (Retsevmo®) Advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over
	TA1040 – Olaparib (Lynparza®) BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
	TA1041 – Durvalumab (Imfinzi®) With etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer
	TA1042 – Selpercatinib (Retsevmo®) Previously treated RET fusion-positive advanced non-small-cell lung cancer
	TA1043 – Osimertinib (Tagrisso®) Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
	TA1044 – Exagamglogene autotemcel (Casgevy®) Severe sickle cell disease in people 12 years and over
	TA1048 – Lisocabtagene maraleucel (liso-cel; Breyanzi®) Relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable
	TA1049 – Blinatumomab (Blinicyto®) With chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
	TA1050 – Fenfluramine (Fintepla®) Seizures associated with Lennox–Gastaut syndrome in people 2 years and over
BLUE	TA1045 - 12 SQ-HDM SLIT (Acarizax®) Allergic rhinitis caused by house dust mites (Replaces TA834)
BLACK	TA1045 - 12 SQ-HDM SLIT (Acarizax®) Allergic asthma caused by house dust mites (Replaces TA834)
	TA1033 - Ganaxolone (Ztalmy®) Seizures caused by CDKL5 deficiency disorder in people 2 years and over
	TA1046 - Zolbetuximab (Vyloy®) With chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
	TA1047 – Atezolizumab Untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)

Useful Information

Next TAG meeting	Wednesday 7th May 2025
Deadline for agenda submissions	Tuesday 29th April 2025
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- **Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates**
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net